1.Wein AJ. Diagnosis and treatment of the overactive bladder. Urology. 2003. 62((5 Suppl 2):):20–7.
Article
2.Temml C., Heidler S., Ponholzer A., Madersbacher S. Prevalence of the overactive bladder syndrome by applying the International Continence Society definition. Eur Urol. 2005. 48:622–7.
Article
3.Yoshimura N., Chancellor MB. Current and future pharmacological treatment for overactive bladder. J Urol. 2002. 168:1897–913.
Article
4.Madersbacher H., Murtz G. E伴icacy, tolerability and safety profile of propiverine in the treatment of the overactive bladder (non-neurogenic and neurogenic). World J Urol. 2001. 19:324–35.
5.Kreder K., Mayne C., Jonas U. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder Eur Urol. 2002. 41:588–95.
6.Andersson KE. Antimuscarinics for treatment of overactive bladder Lancet Neurol. 2004. 3:46–53.
7.Blaivas JG., Groutz A. Bladder outlet obstruction nomogram for women with lower urinary tract symptomatology. Neur-ourol Urodyn. 2000. 19:553–64.
Article
8.Abrams P., Larsson G., Chappie C., Wein AJ. Factors involved in the success of antimuscarinic treatment. BJU Int. 1999. 83(Suppl 2):42–7.
Article
9.Igawa Y. Discussion: functional role of Ml, M2, M3, and M3 muscarinic receptors in overactive bladder. Urology. 2000. 55((5A Suppl):):47–9.
10.Dorschner W., Stolzenburg JU., Griebenow R., Halaska M., Schubert G., Murtz G, et al. Efficacy and cardiac safety of propiverine in eldery patients: a double-blind, placebo-controlled clinical study. Eur Urol. 2000. 37:702–8.
11.Malone-Lee J., Henshaw DJ., Cummings K. Urodynamic verification of an overactive bladder is not a prerequisite for antimuscarinic treatment response. BJU Int. 2003. 92:415–7.
Article
12.Kim JC. “ Neuronal-like” properties of urothelium in bladder. J Korean Continence Soc. 2001. 5:12–23.
13.Vlaskovska M., Kasakov L., Rong W., Bodin P., Bardini M., Cockayne DA, et al. P2X3 knock-out mice reveal a major sensory role for urothelially released ATP. J Neurosci. 2001. 21:5670–7.
14.Cockayne DA., Hamilton SG., Zhu QM., Dunn PM., Zhong Y., Novakovic S, et al. Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X3-deficient mice. Nature. 2000. 407:1011–5.
Article
15.Holladay MW., Dart MJ., Lynch JK. Neuronal nicotinic acetylcholine receptors as targets for drug discovery. J Med Chem. 1997. 40:4169–94.
Article
16.Beckel JM., Kanai A., Lee SJ., de Groat WC., Birder LA. Expression of functional nicotinic acetylcholine receptors in rat urinary bladder epithelial cells. Am J Physiol Renal Physiol. 2006. 290:F103–10.
Article
17.Kim JC., Kim DB., Seo SI., Park YH., Hwang TK. Nerve growth factor and vanilloid receptor expression, and detrusor instability, after relieving bladder outlet obstruction in rats. BJU Int. 2004. 94:915–8.
Article
18.Kim JC., Park EY., Seo SI., Park YH., Hwang TK. Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder. J Urol. 2006. 175:1773–6.
Article
19.Braverman AS., Ruggieri MR Sr. Hypertrophy changes the muscarinic receptor subtype mediating bladder contraction from M3 toward M2. Am J Physiol Regul Integr Comp Physiol. 2003. 285:R701–8.